After finding that immune checkpoint inhibitors (ICIs) do not work as well for patients who had taken antibiotics, the investigators suggest restoring the gut microbiome before starting therapy.
Twelve genetic mutations in clear-cell renal cell carcinoma may predict which patients will experience recurrence; they could also help personalize adjuvant treatment, researchers say.
A unique study in patients with renal cell carcinoma on tyrosine kinase inhibitors (TKIs) shows that taking a break from the drugs is feasible and cost-effective.
First-line nivolumab plus cabozantinib continues to show superiority to sunitinib in the treatment of patients with advanced advanced renal cell carcinoma (RCC).